Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Utah Medical ProductsFRA:UTM -2.50%73 EV-to-EBITDA is 10.47 as of Aug. 27, 2026, which is 2% below its 10-year median of 10.69. GuruFocus rates FRA:UTM with a GF Score™ of 73/100 and a GF Value™ of €49.20. The stock has 8 warning signs investors should review. Among 521 Medical Devices & Instruments companies, Utah Medical Products ranks better than 63.34% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Utah Medical Products's enterprise value is €118.52 Mil.
Utah Medical Products's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €11.32 Mil. Therefore, Utah Medical Products's EV-to-EBITDA for today is 10.47.
The historical rank and industry rank for Utah Medical Products's EV-to-EBITDA or its related term are showing as below:
FRA:UTM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.61 Med: 10.69 Max: 17.49
Current: 10.42
During the past 13 years, the highest EV-to-EBITDA of Utah Medical Products was 17.49. The lowest was 5.61. And the median was 10.69.
FRA:UTM's EV-to-EBITDA is ranked better than 63.34% of 521
companies
in the Medical Devices & Instruments industry
Industry Median: 14.67
vs FRA:UTM: 10.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Utah Medical Products (FRA:UTM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Utah Medical Products's PE Ratio (TTM) for today is calculated as:
Utah Medical Products's share price for today is €58.50.
Utah Medical Products's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.822.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Utah Medical Products EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Utah Medical Products's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTM vs EMBC, SMTI, PDEX: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Utah Medical Products's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Utah Medical Products EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Utah Medical Products's EV-to-EBITDA falls into.
Utah Medical Products's current Enterprise Value is €118.52 Mil.
Utah Medical Products's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Utah Medical Products (FRA:UTM) has a EV-to-EBITDA of 10.47 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Utah Medical Products. This is near median its historical median of 10.69. Over the past decade, Utah Medical Products' EV-to-EBITDA has ranged from 5.61 to 17.49. According to the industry distribution chart, Utah Medical Products ranks #191 out of 521 companies in the Medical Devices & Instruments industry, placing it in the top 36.7%.
Is Utah Medical Products' EV-to-EBITDA too high?
Utah Medical Products' current EV-to-EBITDA of 10.47 is near median its 10-year median of 10.69. Over the past 10 years, this metric has ranged from a low of 5.61 to a high of 17.49. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.67. Utah Medical Products' value of 10.47 is 28.6% below this industry median. Based on the distribution chart, Utah Medical Products ranks #191 out of 521 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Utah Medical Products has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' EV-to-EBITDA compare to EMBC and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Utah Medical Products ranks #191 out of 521 companies for EV-to-EBITDA. This puts Utah Medical Products in the upper half of its industry. The industry median EV-to-EBITDA is 14.67. Utah Medical Products' value of 10.47 is 28.6% below this benchmark. Historically, Utah Medical Products' own EV-to-EBITDA has ranged from 5.61 to 17.49 over the past decade. While the company's 10-year median is 10.69 vs. the industry median of 14.67, Utah Medical Products has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.67, based on 521 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Utah Medical Products's current EV-to-EBITDA of 10.47 is 28.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Utah Medical Products. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Utah Medical Products's current EV-to-EBITDA is 10.47, which is near median its own 10-year median of 10.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Utah Medical Products (FRA:UTM) has a current EV-to-EBITDA of 10.47. The stock's GF Value™ is €49.20, compared to a current price of €58.50 — trading 18.9% above its estimated fair value. The current EV-to-EBITDA is 10.47, which is near median its 10-year median of 10.69 and 28.6% below the Medical Devices & Instruments industry median of 14.67. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Utah Medical Products (FRA:UTM), the current EV-to-EBITDA is 10.47 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Utah Medical Products (FRA:UTM) Overvalued in 2026?
Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued.
The current stock price of €58.50 is trading 18.9% above its estimated GF Value™ of €49.20.
Key valuation signals for FRA:UTM:
EV-to-EBITDA: 10.47 (near median its 10-year median of 10.69)
GF Value™: €49.20 vs. price of €58.50 (18.9% above fair value)
Industry Position: 28.6% below the Medical Devices & Instruments median (#191 of 521)
No single metric tells the full story. See the FRA:UTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score
Get the complete analysis for FRA:UTM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTM has been successfully added to your 
